Japan Approves CyberKnife System For Extracranial Use - Non-Invasive Treatment Alternative For Tumors Anywhere In The Body

Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) has granted Shonin approval of the CyberKnife Robotic Radiosurgery System for use in treatment of extracranial tumors, including tumors that move with respiration.

ChemGenex's Omacetaxine Demonstrates Activity In CML Patients Who Have Failed Therapy With Multiple Tyrosine Kinase Inhibitors

ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced the presentation of positive preliminary results from a phase 2 study of omacetaxine mepesuccinate (formerly known as Ceflatonin ) in chronic myeloid leukemia (CML) patients who have failed therapy with at least two tyrosine kinase inhibitors (TKIs).

Talking About Sad, Bad And Difficult Issues In Cancer - ESMO And CRUK Partner On A Communication Skills Course For Oncologists

An innovative course designed to help oncologists overcome communication barriers when talking to patients and their families will be organized in Buckinghamshire, UK from 18-20 June 2008 by the European Society for Medical Oncology (ESMO).

Patient's Own Infection-fighting T Cells Put Late-stage Melanoma Into Long-term Remission

Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine.

BioInvent And ThromboGenics Announce A Strategic Alliance With Roche For TB-403, A Novel Anti-Cancer Antibody

BioInvent International AB (STO:BINV) and ThromboGenics NV (Euronext Brussels: THR) announce that they have entered into a license agreement with Roche (SWX: ROG) for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels.

First Patient Dosed In A Phase 1 Clinical Trial With Oral TRC102, An Inhibitor Of Chemotherapy Resistance, In Combination With Alimta reg;

TRACON Pharmaceuticals, Inc., announced that the first cancer patient has been treated in a Phase 1 clinical trial with oral TRC102, a novel anti-cancer drug intended to reverse resistance to Alimta chemotherapy by targeting a specific DNA repair pathway.

First Semiconductor-Based PET Scanner Demonstrates Potential To Aid In Early Diagnosis Of Disease

Evaluations of the first-ever prototype positron emission tomography (PET) brain scanner that uses semiconductor detectors indicate that the scanner could advance the quality and spatial resolution of PET imaging, according to researchers at SNM's 55th Annual Meeting.

Newcastle Scientists Make Breakthrough In Treatment For Blood Cancer

Newcastle University researchers, funded by leading blood cancer charity Leukaemia Research, have made significant progress in the development of improved treatments for chronic lymphocytic leukaemia, the commonest leukaemia in adults in the UK.

Anti-Cancer Molecules Predicted By Computer

A new computer-based method of analyzing cellular activity has correctly predicted the anti-tumour activity of several molecules. Research published in BioMed Central's open access journal Molecular Cancer describes 'CoMet' - a tool that studies the integrated machinery of the cell and predicts those components that will have an effect on cancer.

EMEA Recommends Information On Lung Cancer Cases To Be Included In Exubera Product Information, Europe

The European Medicines Agency (EMEA) has recommended that the product information for Exubera be updated with new information on cases of lung cancer seen in patients taking the medicine. Exubera, from Pfizer Limited, is a fast-acting insulin powder for inhalation, used for the treatment of adults with type 1 or type 2 diabetes.